Navigation Links
Blood Thinner OK for Superficial Leg Clots: Study
Date:9/22/2010

By Randy Dotinga
HealthDay Reporter

WEDNESDAY, Sept. 22 (HealthDay News) -- A blood-thinning drug could help some patients with superficial-vein thrombosis avoid more serious blood clots, a new study suggests. But experts question whether the benefit is worth the drug's high price.

Superficial-vein thrombosis, or superficial phlebitis, is characterized by blood clots in leg veins close to the skin. "This clot occurs in 90 percent of cases of varicose veins and is painful and visible for the patient," said the study's lead author, Dr. Herve Decousus, a researcher with University Hospital in Saint-Etienne, France.

Many factors -- long flights, pregnancy or recent surgery, among them -- can cause the condition. While serious complications of superficial-vein clots are rare, people with the condition can be at risk of developing deep-vein thrombosis, which is more serious and potentially fatal. Some doctors treat the superficial clots with blood-thinning medication or surgery; others don't treat them at all.

In the new study, researchers treated the superficial clots with Arixtra (fondaparinux), which is used to prevent and treat clots in the deep veins of the legs and in the lungs (pulmonary embolism), or a placebo. The pharmaceutical company GlaxoSmithKline, which makes Arixtra, funded the study.

Researchers randomly assigned 3,002 patients to receive either injections of 2.5 mg of Arixtra daily or a placebo for 45 days. They monitored the patients for another 32 days.

The study findings appear in the Sept. 23 issue of The New England Journal of Medicine.

The risk of developing deep-vein blood clots or clots in the lungs was lower in those who took the drug: 0.2 percent in those taking Arixtra vs. 1.3 percent in those getting the placebo.

The researchers also found that the risk of serious adverse events was less in the Arixtra group (0.7 percent) compared with the placebo group (1.1 percent). One patient in each group suffered major bleeding, they said.

"This treatment is effective, safe and relatively simple," Decousus said.

However, the risk of death -- one in 1,000 -- was the same in both groups. And overall, the researchers estimated that they'd have to treat 88 people with the drug to prevent one case of a deep-vein or lung blood clot.

Since the drug is safe, Decousus said, it's an acceptable treatment. "There are many diseases with a low risk of mortality which, nevertheless, require effective treatment to prevent disabling complications and the need for more aggressive therapies such as surgery."

But one American expert was more cautious. Dr. Julie Freischlag, director of the department of surgery at Johns Hopkins School of Medicine in Baltimore, said that it was rare that the clots would pose a serious threat. The findings "didn't convince me to use this in all patients. I've only seen a few clots go deeper," she said.

And in an accompanying commentary in the journal, two American doctors cautioned that the drug is expensive, costing $2,124 to $7,380 in New York City for a once-daily, 45-day supply. They recommended that government officials spend more time studying the drug and its cost-effectiveness. Until there's a consensus, they wrote, "it would be premature" to recommend the drug for this use.

More information

For more about superficial-vein thrombosis, visit the U.S. National Library of Medicine.

SOURCES: Herve Decousus, M.D., researcher, University Hospital, Saint-Etienne, France; Julie Freischlag, M.D., director, department of surgery, Johns Hopkins School of Medicine, Baltimore; Sept. 23, 2010, New England Journal of Medicine


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Inflammatory Bowel Ups Risk for Blood Clots
2. Bowel disease link to blood clots
3. Local Blood Supply Impacted by Wednesdays Severe Snow Storm
4. PERSONALABS Offers Discounted Healthy Heart Online Blood Tests in February
5. China Cord Blood Corporation Warrant Registration Statement Declared Effective by SEC
6. NIH grants to Childrens Hospital will advance novel stem cell treatments for blood disorders
7. Bilberry Seems to Act Against Blood Sugar
8. Johns Hopkins scientists develop personalized blood tests for cancer using whole genome sequencing
9. UCR researcher identifies mechanism malaria parasite uses to spread in red blood cells
10. NHLBI, CDC launch surveillance and research program for inherited blood diseases
11. IOM report declares high blood pressure a neglected disease
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Blood Thinner OK for Superficial Leg Clots: Study
(Date:10/13/2017)... ... 13, 2017 , ... Coveros, a leader in agile coaching ... contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise Agile ... of Agile methodologies in a consistent and high value manner across CMS programs. ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the ... “America On The Brink” is the creation of published author, William Nowers. Captain ... As a WWII veteran, he spent thirty years in the Navy. Following his ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and ... apnea using cutting-edge Oventus O2Vent technology. As many as 18 million Americans ... frequent cessation in breathing. Oral appliances can offer significant relief to about 75 ...
(Date:10/12/2017)... ... 12, 2017 , ... The company has developed a suite ... regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been developed ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, ...
(Date:10/12/2017)... ... ... The American College of Medical Informatics (ACMI) will present the 2017 Morris ... of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is taking ... in the field of medical informatics, this prestigious award is presented to an individual ...
Breaking Medicine News(10 mins):
(Date:10/4/2017)... to the Centers for Disease Control and Prevention (CDC), influenza vaccination ... is helping communities across Massachusetts , Connecticut ... flu shots through the end of the month. *Some exclusions ... ... shot is by the end of October, according to the Centers for ...
(Date:10/2/2017)... 2, 2017  AllianceRx Walgreens Prime, the combined central ... and pharmacy benefit manager Prime Therapeutics LLC (Prime), today ... included the unveiling of new signage at its headquarters ... as at a few other company-owned facilities across the ... patients, some of whom will begin to see the ...
(Date:9/28/2017)... , Sept. 28, 2017 Cohen Veterans ... advance the use of wearable and home sensors for ... disorders. Early Signal Foundation, a nonprofit organization focused on ... will provide an affordable analytical system to record and ... ...
Breaking Medicine Technology: